Published in Gene Therapy Weekly, December 21st, 2000
But while transduction was demonstrated, the therapeutic value of the treatment was limited.
Researchers pursued the naked DNA injection approach to gene delivery because viral vectors of direct intra-articular gene therapy bring with them some inherent obstacles, such as variable host response to viral proteins as well as incorporation into host DNA, explained D.L. Boyle and colleagues in a presentation to the joint 64th annual scientific meeting of the American College of Rheumatology and the 35th annual meeting of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2000-12-21)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.